Background. The positive impact of opioid substitution treatment (OST) on opioid-dependent individuals with human immunodeficiency virus (HIV) infection is well documented, especially with regard to adherence to highly active antiretroviral therapy (HAART). We used the data from a 5-year longitudinal study of the MANIF 2000 cohort of individuals infected with HIV (as a result of injection drug use) and receiving HAART to investigate the predictors of long-term virological success.
Since the emergence and spread of human immunodeficiency virus (HIV) infection, injection drug users (IDUs) have been considered a difficult-to-treat population because of their lifestyle instability. As a con-sequence, they may not have benefited from highly active antiretroviral therapy (HAART) to the same extent as other HIV transmission categories [1] . This is primarily due to physicians' perceptions of ongoing drug users as a population unable to maintain adherence to HAART [2] , and consequently physicians may be more prone to denying or delaying HAART until patients' stabilize their lifestyles [1] . However, IDUs who receive and adhere to HAART have HIV outcomes comparable to those of non-IDUs [3] . Moreover, because treatment with methadone or buprenorphine can help stabilize patients and improve social rehabilitation [4] , these opioids were included in the World Health Organiza-tion's 14 edition of the model list of essential medicines [5] . This decision was based on several results that consistently showed that providing adequate care to drug-dependent HIVinfected IDUs can improve adherence to HIV treatment [6, 7] . In those studies, adherence was used as a proxy of virological response to HAART, because its efficacy relies on a high level of adherence [3, 8] . In reality, HIV-infected opioid-dependent individuals receiving opioid substitution treatment (OST) in a comprehensive model of care are more likely to start HAART sooner [9] , thereby avoiding the usual long delays in access to antiretroviral drugs that may be responsible for the difference in HIV progression observed between IDUs and non-IDUs.
Additionally, in our study, it is possible that the patients receiving HAART whose conditions stabilized during OST were also less likely to have their HAART interrupted and that the duration of OST may have captured an additional dimension of adherence to HAART, which was in turn related to routine patient behaviors. The present study greatly extends the findings of Duran et al [10] , reporting a more complete analysis of the contribution of OST and important covariates to virological success. To date, no study has reported whether and to what extent stabilization during OST can contribute to long-term virological suppression for patients receiving HAART. The MANIF 2000 cohort study provided us with the opportunity to investigate whether retention in OST for HIV-infected IDUs is associated with long-term virological success, independent of HAART adherence, early virological response, or other known predictors.
METHODS
In 1995-1996, the French MANIF 2000 cohort enrolled 467 patients infected with HIV as a result of injection drug use. Inclusion criteria for enrollment in the cohort were that patients had to be at clinical stage A or B and have a CD4 + cell count of 1300 cells/mm 3 at their last visit prior to enrollment. This cohort was designed to focus on the sociobehavioral characteristics of HIV-positive IDUs, with particular emphasis on their access and adherence to antiretroviral treatment.
Study group. First, we selected all the MANIF 2000 patients who started HAART at least 6 months ago (baseline visit) and collected data on all their follow-up visits while they were still receiving HAART. Patients who were no longer dependent on opioids (ie, abstinent from heroin, morphine, buprenorphine, or methadone during the entire period of the follow-up) were excluded from the analysis. In this way, we included all patients who could potentially have indications for OST (ie, still dependent on opioids). Second, for the selected study group, at any given follow-up visit, patients could be defined as receiving OST (methadone or buprenorphine), as being a candidate for OST, or as having their OST discontinued or interrupted. In the end, 113 individuals were selected, accounting for a total of 562 visits for all the analyses.
Data collection. Data collection was scheduled every 6 months. Face-to-face interviews were conducted to gather psychosocial information about patients' personal experiences with HIV infection and care. A self-administered questionnaire was used to collect sociodemographic data (eg, details about prison history, drug and alcohol use, and related behaviors) and data on patients' access to OST (methadone or buprenorphine) during the past 6 months. Patients' self-reported answers concerning heroin and morphine use were validated at enrollment by the detection of morphine in urine samples [11] . Information about adherence to HAART was obtained from the selfadministered questionnaires and the face-to-face interviews, in accordance with the methods of the Adult AIDS Clinical Trial Group [12] . At any given visit, patients were considered "adherent" if they reported in the interview that they had taken 100% of the total dose of prescribed drugs during the previous month. This approach has been previously validated using protease inhibitor concentrations [10] and has been thoroughly described elsewhere in a previous publication [13] . For our analysis, we used a question about HAART interruption in the month prior to the visit to build a 3-category adherence indicator: high adherence (100% adherence to HAART), missed doses (!100% adherence to HAART without interruption), and treatment interruption (having reported HAART interruption during the previous month).
Depression was measured using the French version of the Center for Epidemiological Studies Depression Scale [14] , which has a score that ranges from 0 to 60. The score was then dichotomized using 17 and 23 as cutoff points for men and women, respectively, and any score higher than those respective cutoff points was an indication of depressive symptoms [15] .
Clinical and laboratory data (such as viral load and CD4 + cell count) came from the physician or from the patient's medical records and were collected every 6 months. Patients were considered to have achieved virological success if they had an undetectable viral load, which was defined as an HIV-1 RNA level below the lower limit of detection of the assay. Data on HIV clinical stage were recovered from medical records. Longterm virological success was defined as achieving an undetectable viral load after at least 6 months of HAART. The second visit to the physician by the patient receiving HAART was defined in our study as the baseline visit. An early virological response was defined as the achievement of an undetectable viral load during the first 6 months of HAART. We tested 4 variables concerning exposure to OST: retention in OST, type of OST, interruption of OST, and the global duration of OST during HAART follow-up. All this information was evaluated using both patients' and physicians' answers to the questionnaires. Although negligible differences were ob- served between physicians' and patients' self-reports about OST, in case of disagreement, we considered patients' self-reports to be more reliable. If a patient was still on OST at any given visit, retention in OST was defined as the time interval between the last initiation or reinitiation of OST during HAART follow-up and that visit. Any interruption of OST during HAART followup reset the clock computing retention in OST back to zero. To study the difference between receiving methadone or buprenorphine, we tested the variable "type of OST," which was defined as reporting receiving methadone or buprenorphine at given any visit.
The variable "interruption of OST" was tested by computing the number of OST interruptions. A global indicator, entitled "global OST duration" whether interrupted or not, was also computed by cumulating the months spent on OST during the whole HAART follow-up period.
Statistical analyses. A mixed logistic regression was used to identify predictors of long-term virological success for patients receiving HAART who had indications for OST or who were receiving OST. We focused on the measures of viral load (detectable or undetectable) during the maintenance phase (ie, after at least 6 months of HAART), modeling data on virological success for the longitudinal study and thereby assessing the impact of fixed and time-varying variables on this outcome [16] . The patient was considered as a "unit" characterized by multiple observations over time. In this way, a random effect was added to the intercept to take into account the intraindividual correlation of measures in the mixed model analysis. All factors potentially associated with the outcome were tested as fixed effects in univariate mixed logistic regression models. Variables that reached a significance level of in the P р .25 univariate analyses were considered eligible for inclusion in the multivariate model. A backward elimination approach based on mixed logistic regression was used to identify the best set of predictors of outcome and to estimate adjusted odds ratios (ORs) and their 95% confidence intervals (CIs). Variables were considered to be significantly associated with virological success on the basis of the log-likelihood ratio test (
). All the P р .05 analyses were performed using Stata, version 10.0 (StataCorp).
To verify whether retention in OST captured moderate adherence behaviors known to be associated with long-term virological success [17] , we performed a sensitivity analysis to see whether changing the cutoff for adherence would lower the association between retention in OST and long-term virological success.
RESULTS
Of the 113 patients, 30 (26.5%) were women, and 83 (73.5%) were male. The median age was 36 years (interquartile range [IQR], 32-39 years) at their first available visit during followup (Table 1) . At baseline, 53 (46.9%) patients were receiving buprenorphine, 28 (24.8%) were receiving methadone, and 32 (28.3%) were not receiving OST. Nearly half of the patients (ie, 59 patients [52.2%]) reported 100% adherence to HAART at the baseline visit (42% of IDUs and 57% of non-IDUs reported 100% adherence). At baseline, 42 patients (37.2%) had an undetectable viral load (29% of IDUs and 40% of non-IDUs had an undetectable viral load). The median duration of retention in OST was 25 months (IQR, 3-42 months). During the whole study follow-up period, 6 patients switched from buprenorphine to methadone, and 2 patients switched from methadone to buprenorphine. Twenty patients experienced an OST interruption, and 4 patients experience an interruption OST twice during follow-up. Thirty-four (30.1%) patients reported, at least once during follow-up, to have injected drugs during the previous 6 months. Of the 113 patients, 79 (70.0%) achieved virological success at least once during HAART followup, accounting for 214 (38.1%) of the 562 visits. NOTE. All factors potentially associated with the outcome were tested as fixed effects in univariate mixed logistic regression models. CI, confidence interval; IQR, interquartile range; OR, odds ratio.
a Per 10-year increase. b Defined as alcohol consumption of 1150 units per month for men and of 1100 units per month for women. c Depression was measured using the French version of the Center for Epidemiological Studies Depression Scale [14] , which has a score that ranges from 0 to 60. The score was then dichotomized using 17 and 23 as cutoff points for men and women, respectively, and any score higher than those respective cutoff points was an indication of depressive symptoms [15] . d Per 6-month increase.
The results of the univariate analysis are presented in Table  2 . Patients who received buprenorphine or methadone while on HAART were more likely to achieve virological suppression during follow-up visits, compared with the patients who did not receive OST. It is interesting to note that those patients who received buprenorphine or methadone while on HAART had an ∼2-fold or ∼4-fold increased likelihood of virological success, respectively, when compared with patients who did not receive OST. Moreover, patients who reported alcohol binge drinking and cocaine use were less likely to achieve long-term virological success. Longer duration of retention in OST since HIV diagnosis or HAART initiation and no previous exposure to antiretroviral drugs before HAART initiation were both associated with long-term virological success in the univariate analysis.
In model 1 of the multivariate analysis (Table 3) , adherence to HAART and early virological response were among the known predictors of long-term virological success. More precisely, patients who reported an interruption in HAART (OR, 0.21; 95% CI, 0.06-0.71) and patients with missed doses (without treatment interruption) during the previous month (OR, 0.57; 95% CI, 0.32-1.00) were less likely to have achieved virological success. More interestingly, the longer the duration of retention in OST, the higher the likelihood of achieving longterm virological success (OR, 1.20 per 6-month increase; 95% CI, 1.08-1.32), independent of adherence to HAART. The relationship between retention in OST and nonadherence was tested, but it did not reach statistical significance ( ). P p .08 The sensitivity analysis, performed using 80% as a cutoff point for the adherence indicator, confirmed the same pattern of correlates with identical OR estimates, with the exception of adherence, which did not remain significantly associated with the outcome. To study the impact of the type of OST on the outcome, we replaced retention in OST with treatment with methadone or buprenorphine (model 2 in Table 3 ). Patients who were treated with methadone were more likely than patients who were treated with buprenorphine to achieve an undetectable viral load during the maintenance phase of HAART ( vs ). Retention in buprenorphine treatment P p .006 P p .14 and retention in methadone treatment were significantly associated with outcome when included in model 3 (Table 3) . It is important to note that there was a statistically significant difference ( ) between retention in buprenorphine (me-P p .02 dian duration, 35 months [IQR, 14-52 months]) and retention in methadone (median duration, 44 months [IQR, 30-59 months]). Interruption of OST as a time-varying variable was not associated with outcome (OR, 1.4; 95% CI, 0.7-2.8), whereas global duration of OST (OR, 1.17 per 6-month increase; 95% CI, 1.06-1.29) was significantly associated longterm virological success.
DISCUSSION
Our study presents important evidence of the positive impact of retention in OST on HIV outcomes; for HIV-infected IDUs who received both HAART and OST, the longer the duration of retention in OST, the higher the likelihood of long-term virological success. This result remains valid even after adjustment for known correlates of virological success among patients who received HAART, such as self-reported adherence [17] and early virological response to HAART [18] . To our knowledge, this is the first study to demonstrate such a positive impact of retention in OST on long-term virological success among HIVinfected patients on HAART. Several hypotheses could be developed to explain the impact of retention in OST on HIV viral load as revealed in our study.
First, it is possible that retention also captured a component of adherence to HAART that remained undetected by our indicator of adherence. Consequently, we verified whether a shorter duration of retention in OST could be a proxy of HAART interruption. The results confirmed that retention in OST remains a major predictor of virological success, independently of missed doses and HAART interruptions. The benefit of separating the category of missed doses from the category of treatment interruption in evaluating adherence to HAART was confirmed by the very high risk of virological failure observed among patients who experienced an interruption in HAART, something which has already been shown in previous research [19] . In addition, we verified whether the chosen cutoff point (100%) for adherence was too strict and whether a lower cutoff point (ie, one that included patients moderately and fully adherent to HAART) could have predicted an undetectable viral load more accurately. However, examining this issue using a sensitivity analysis based on an 80% cutoff point for adherence did not modify the association between retention in OST and long-term virological success. Furthermore, the results show that retention in OST is only weakly associated with nonadherence.
Second, retention in OST may be a proxy for longer delays before initiation of HAART. When HAART first started to become available, physicians tended to delay access to HAART for active IDUs because of presumed suboptimal adherence [1] , whereas recent results show that early initiation of HAART may counterbalance the "costs" of nonadherence [20] . One of the reasons for delayed access was that, in accordance with past guidelines, IDUs were more likely to receive HAART only if their opioid dependence was stabilized by OST [21] . Because variations in viral load during HAART strongly depends on delayed access [22] and long-term adherence to HAART, it is possible that the duration of OST may not only be a rough proxy for shorter delays in accessing HAART but also for improved comprehensive care, including care for psychiatric comorbidities and general health [23] .
Another hypothesis that may explain our main result is the possibility that a shorter duration of retention characterizes individuals who cycle in and out of OST [24] and who, as a result, remain more exposed to injection drugs [25] ; this type of behavior has already been found to be a predictor of virological failure [26] . Patients exhibiting such behavior remain increasingly more exposed to bacterial infection and reinfection by hepatitis C virus [27] . All these coinfections might explain the increase in HIV viremia [28, 29] . Our results are consistent with those of a different study that investigated the substantial reductions in high-risk behaviors found after 1 year of OST follow-up in terms of injection drug use, the sharing syringes and needles, and inconsistent condom use [30] . However, our hypothesis that the onset of other infections may have an impact on HIV viral load needs to be verified by clinical studies on the mechanism(s) of pathogenesis [31] .
Although both retention in methadone treatment and retention in buprenorphine treatment were significantly associated with virological success, when neglecting the duration of "exposure" to OST, only patients who received methadone experienced a significant positive impact on virological response. This difference may be attributable to 3 factors. First, this variable may be a proxy for retention, because it is known that patients on methadone are more likely to be retained in treatment than are patients on buprenorphine [32] , consistent with the results from our study. This is probably due to the fact that access to methadone in France is characterized by initial screening for patient motivation, that is to say his or her motivation to participate fully in a follow-up treatment program requiring frequent scheduled visits. Second, the difference may be due to the model of care. Buprenorphine is mainly prescribed in primary care, whereas methadone can only be initiated in a medical center for drug dependence where patients receive comprehensive general care and care for psychiatric comorbidities. In effect, the rapid scaling up of buprenorphine in primary care facilities in France has resulted in many physicians receiving inadequate training for the management of drug-dependent patients. Moreover, many physicians practice alone, far from organized networks that deliver care for opioid-dependent individuals [33] . It has already been shown that buprenorphine injection occurs more frequently among patients who are treated in primary care than among patients who are treated in drug treatment centers [34] . Finally, the differences between methadone and buprenorphine treatment should be regarded with caution, because of our study's nonrandom assignment to OST.
Even though OST in primary care presents some weaknesses, it has been shown that office-based management of opioid dependence can be feasible and effective [35] . A previous experiment, which consisted of creating a network that connected HIV specialists, psychiatrists, and hospital-based and primary care teams, showed improved health outcomes for HIV-infected patients who were followed up by general practitioners [36] . Improved communication between primary care physicians and addiction specialists could help primary care physicians become more engaged in drug dependence care and could provide them with appropriate training for the prescription of OST [37] .
Despite some limitations related to the reliability of selfreports, which are often subject to social desirability bias [38] , the sensitivity analysis shows that a 100% cutoff point for selfreported adherence optimizes the relationship between adherence and stable virological response to HAART, because it probably yields improved detection of patients who truly adhere to HAART while minimizing social desirability bias. Furthermore, the study population may be considered representative of the general HIV-infected IDU population in France, because the French health insurance system provides even marginalized populations, including individuals with HIV infection and/or drug dependence, with free access to care [39] .
Our results underline the importance of providing HIV-infected drug users with an appropriate model of comprehensive care, aimed at optimizing retention in OST and HAART. More particularly, this issue highlights the need to provide adequate training of primary care physicians who are likely to consult HIV-infected drug users. Above all, physicians providing HIV care should remain connected with multidisciplinary networks to adequately manage comorbidities and psychosocial problems. While waiting for these conditions to come about in many countries, expanded access to OST remains the sole option for assuring improved HIV prevention and sustained response to HIV care.
